Dave Stack, Pacira BioSciences CEO
September 21, 2022 10:53 AM EDT
R&D

With back-to-back PhI­II wins, Paci­ra guns for ex­pand­ed in­di­ca­tion for post-surgery pain drug Ex­par­el

Lei Lei Wu

News Reporter

Just weeks af­ter it an­nounced a Phase III win for its pain drug af­ter knee re­place­ment, Paci­ra Bio­Sciences has post­ed an­oth­er Phase III suc­cess in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times